Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$52 Mln
P/E Ratio
--
P/B Ratio
0.59
Industry P/E
--
Debt to Equity
0
ROE
-0.7 %
ROCE
--
Div. Yield
0 %
Book Value
1.45
EPS
--
CFO
$-346.87 Mln
EBITDA
$-507.51 Mln
Net Profit
$-477.29 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Kronos Bio Inc (KRON)
| -10.42 | -1.81 | -18.17 | -11.35 | -45.58 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Kronos Bio Inc (KRON)
| -23.83 | -22.84 | -88.08 | -54.50 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor... development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California. Read more
President, CEO & Director
Dr. Norbert W. Bischofberger Ph.D.
President, CEO & Director
Dr. Norbert W. Bischofberger Ph.D.
Headquarters
San Mateo, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Kronos Bio Inc (KRON) stood at $ 240 Mln as on 31-Mar-25
The share price of Kronos Bio Inc (KRON) is $0.85 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Kronos Bio Inc (KRON) has given a return of -45.58% in the last 3 years.
Kronos Bio Inc (KRON) has a market capitalisation of $ 52 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Kronos Bio Inc (KRON) is 0.59 times as on 25-Apr-2025, a 74% discount to its peers’ median range of 2.29 times.
Since, TTM earnings of Kronos Bio Inc (KRON) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Kronos Bio Inc (KRON) and enter the required number of quantities and click on buy to purchase the shares of Kronos Bio Inc (KRON).
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California.
The CEO & director of Dr. Norbert W. Bischofberger Ph.D.. is Kronos Bio Inc (KRON), and CFO & Sr. VP is Dr. Norbert W. Bischofberger Ph.D..
There is no promoter pledging in Kronos Bio Inc (KRON).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Kronos Bio Inc (KRON) | Ratios |
|---|---|
|
Return on equity(%)
|
-82.47
|
|
Operating margin(%)
|
-576.03
|
|
Net Margin(%)
|
-853.66
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Kronos Bio Inc (KRON) was $0 Mln.
$-0.01
(
